130 related articles for article (PubMed ID: 21397718)
1. Characterization and standardization of Sabin based inactivated polio vaccine: proposal for a new antigen unit for inactivated polio vaccines.
Westdijk J; Brugmans D; Martin J; van't Oever A; Bakker WA; Levels L; Kersten G
Vaccine; 2011 Apr; 29(18):3390-7. PubMed ID: 21397718
[TBL] [Abstract][Full Text] [Related]
2. Antigenic and immunogenic properties of inactivated polio vaccine made from Sabin strains.
Kersten G; Hazendonk T; Beuvery C
Vaccine; 1999 Apr; 17(15-16):2059-66. PubMed ID: 10217607
[TBL] [Abstract][Full Text] [Related]
3. Safety and immunogenicity of inactivated poliovirus vaccine based on Sabin strains with and without aluminum hydroxide: a phase I trial in healthy adults.
Verdijk P; Rots NY; van Oijen MG; Oberste MS; Boog CJ; Okayasu H; Sutter RW; Bakker WA
Vaccine; 2013 Nov; 31(47):5531-6. PubMed ID: 24063976
[TBL] [Abstract][Full Text] [Related]
4. An inactivated poliovirus vaccine using Sabin strains produced on the serum-free PER.C6® cell culture platform is immunogenic and safe in a non-human primate model.
Bockstal V; Tiemessen MM; Achterberg R; Van Wordragen C; Knaapen AM; Serroyen J; Marissen WE; Schuitemaker H; Zahn R
Vaccine; 2018 Nov; 36(46):6979-6987. PubMed ID: 30314910
[TBL] [Abstract][Full Text] [Related]
5. Quantitation of D antigen content in inactivated poliovirus vaccine derived from wild-type or sabin strains.
Sawyer LA; McInnis J; Albrecht P
Biologicals; 1993 Jun; 21(2):169-77. PubMed ID: 8297601
[TBL] [Abstract][Full Text] [Related]
6. Differences in Antigenic Structure of Inactivated Polio Vaccines Made From Sabin Live-Attenuated and Wild-Type Poliovirus Strains: Impact on Vaccine Potency Assays.
Crawt L; Atkinson E; Tedcastle A; Pegg E; ; Minor P; Cooper G; Rigsby P; Martin J
J Infect Dis; 2020 Feb; 221(4):544-552. PubMed ID: 30788503
[TBL] [Abstract][Full Text] [Related]
7. Universal ELISA for quantification of D-antigen in inactivated poliovirus vaccines.
Kouiavskaia D; Puligedda RD; Dessain SK; Chumakov K
J Virol Methods; 2020 Feb; 276():113785. PubMed ID: 31765719
[TBL] [Abstract][Full Text] [Related]
8. Inactivated polio vaccine development for technology transfer using attenuated Sabin poliovirus strains to shift from Salk-IPV to Sabin-IPV.
Bakker WA; Thomassen YE; van't Oever AG; Westdijk J; van Oijen MG; Sundermann LC; van't Veld P; Sleeman E; van Nimwegen FW; Hamidi A; Kersten GF; van den Heuvel N; Hendriks JT; van der Pol LA
Vaccine; 2011 Sep; 29(41):7188-96. PubMed ID: 21651934
[TBL] [Abstract][Full Text] [Related]
9. Immunity status of adults and children against poliomyelitis virus type 1 strains CHAT and Sabin (LSc-2ab) in Germany.
Eggers M; Terletskaia-Ladwig E; Rabenau HF; Doerr HW; Diedrich S; Enders G; Enders M
BMC Infect Dis; 2010 Dec; 10():347. PubMed ID: 21143885
[TBL] [Abstract][Full Text] [Related]
10. Potency of wild-type or sabin trivalent inactivated poliovirus vaccine, by enzyme-linked immunosorbent assay using monoclonal antibiotics specific for each antigenic site.
Sawyer LA; Wood D; Ferguson M; Crainic R; Beuvery EC; McInnis J; Albrecht P
Biologicals; 1997 Sep; 25(3):299-306. PubMed ID: 9324998
[TBL] [Abstract][Full Text] [Related]
11. Antigen sparing with adjuvanted inactivated polio vaccine based on Sabin strains.
Westdijk J; Koedam P; Barro M; Steil BP; Collin N; Vedvick TS; Bakker WA; van der Ley P; Kersten G
Vaccine; 2013 Feb; 31(9):1298-304. PubMed ID: 23313617
[TBL] [Abstract][Full Text] [Related]
12. Effects of the thermal denaturation of Sabin-derived inactivated polio vaccines on the D-antigenicity and the immunogenicity in rats.
Murakami K; Fujii Y; Someya Y
Vaccine; 2020 Apr; 38(17):3295-3299. PubMed ID: 32197923
[TBL] [Abstract][Full Text] [Related]
13. Antigenic characterization of a formalin-inactivated poliovirus vaccine derived from live-attenuated Sabin strains.
Tano Y; Shimizu H; Martin J; Nishimura Y; Simizu B; Miyamura T
Vaccine; 2007 Oct; 25(41):7041-6. PubMed ID: 17825459
[TBL] [Abstract][Full Text] [Related]
14. Increased potency of an inactivated trivalent polio vaccine with oil-in-water emulsions.
Baldwin SL; Fox CB; Pallansch MA; Coler RN; Reed SG; Friede M
Vaccine; 2011 Jan; 29(4):644-9. PubMed ID: 21134451
[TBL] [Abstract][Full Text] [Related]
15. A national reference for inactivated polio vaccine derived from Sabin strains in Japan.
Shirato H; Someya Y; Ochiai M; Horiuchi Y; Takahashi M; Takeda N; Wakabayashi K; Ouchi Y; Ota Y; Tano Y; Abe S; Yamazaki S; Wakita T;
Vaccine; 2014 Sep; 32(40):5163-9. PubMed ID: 25090648
[TBL] [Abstract][Full Text] [Related]
16. Progress with inactivated poliovirus vaccines derived from the Sabin strains.
Doi Y; Abe S; Yamamoto H; Horie H; Ohyama H; Satoh K; Tano Y; Ota Y; Miyazawa M; Wakabayashi K; Hashizume S
Dev Biol (Basel); 2001; 105():163-9. PubMed ID: 11763324
[TBL] [Abstract][Full Text] [Related]
17. Chitosan as an adjuvant for poliovaccine.
Ghendon Y; Markushin S; Akopova I; Koptiaeva I; Krivtsov G
J Med Virol; 2011 May; 83(5):847-52. PubMed ID: 21412793
[TBL] [Abstract][Full Text] [Related]
18. Skin delivery of trivalent Sabin inactivated poliovirus vaccine using dissolvable microneedle patches induces neutralizing antibodies.
Donadei A; Kraan H; Ophorst O; Flynn O; O'Mahony C; Soema PC; Moore AC
J Control Release; 2019 Oct; 311-312():96-103. PubMed ID: 31484041
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of immunogenicity and protective properties of inactivated poliovirus vaccines: a new surrogate method for predicting vaccine efficacy.
Dragunsky EM; Ivanov AP; Wells VR; Ivshina AV; Rezapkin GV; Abe S; Potapova SG; Enterline JC; Hashizume S; Chumakov KM
J Infect Dis; 2004 Oct; 190(8):1404-12. PubMed ID: 15378432
[TBL] [Abstract][Full Text] [Related]
20. Analysis of antigenic profiles of inactivated poliovirus vaccine and vaccine-derived polioviruses by block-ELISA method.
Rezapkin G; Martin J; Chumakov K
Biologicals; 2005 Mar; 33(1):29-39. PubMed ID: 15713554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
